Syndax Pharmaceuticals Inc (NASDAQ: SNDX) kicked off on Thursday, up 4.43% from the previous trading day, before settling in for the closing price of $11.05. Over the past 52 weeks, SNDX has traded in a range of $9.66-$25.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 1801.91% over the past five years. While this was happening, its average annual earnings per share was recorded -3.79%. With a float of $84.18 million, this company’s outstanding shares have now reached $85.69 million.
Let’s look at the performance matrix of the company that is accounted for 270 employees. In terms of profitability, gross margin is -87.26%, operating margin of -1434.43%, and the pretax margin is -1346.11%.
Syndax Pharmaceuticals Inc (SNDX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Syndax Pharmaceuticals Inc is 2.18%, while institutional ownership is 111.89%. The most recent insider transaction that took place on Mar 04 ’25, was worth 117,564. In this transaction Chief Executive Officer of this company sold 7,814 shares at a rate of $15.05, taking the stock ownership to the 300,121 shares. Before that another transaction happened on Mar 04 ’25, when Company’s Officer proposed sale 13,888 for $15.48, making the entire transaction worth $214,986.
Syndax Pharmaceuticals Inc (SNDX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.50% during the next five years compared to -15.16% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Take a look at Syndax Pharmaceuticals Inc’s (SNDX) current performance indicators. Last quarter, stock had a quick ratio of 5.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 41.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -2.80 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) saw its 5-day average volume 1.57 million, a negative change from its year-to-date volume of 2.13 million. As of the previous 9 days, the stock’s Stochastic %D was 65.46%. Additionally, its Average True Range was 0.95.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 23.98%, which indicates a significant decrease from 56.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 91.08% in the past 14 days, which was higher than the 58.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.54, while its 200-day Moving Average is $16.95. Nevertheless, the first resistance level for the watch stands at $11.80 in the near term. At $12.07, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.56. If the price goes on to break the first support level at $11.04, it is likely to go to the next support level at $10.55. The third support level lies at $10.28 if the price breaches the second support level.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
The company with the Market Capitalisation of 992.95 million has total of 86,044K Shares Outstanding. Its annual sales at the moment are 23,680 K in contrast with the sum of -318,760 K annual income. Company’s last quarter sales were recorded 7,680 K and last quarter income was -94,170 K.
